ClinicalTrials.Veeva

Menu
H

Houston Center for Clinical Research | Sugar Land, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

TAK-279
Difamilast
BAY3427080
Semaglutide
MOB015B
Zasocitinib
Elinzanetant
Vilaprisan
Deucravacitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 12 total trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting
Plaque Psoriasis
Drug: TAK-279
Drug: Placebo

The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque...

Enrolling
Plaque Psoriasis
Drug: Zasocitinib
Drug: Placebo to match zasocitinib

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Enrolling
Plaque Psoriasis
Drug: TAK-279

This is a Phase 3 multicenter, double-blind study to evaluate the safety and efficacy of vehicle-controlled topical MOB015B in the treatment of Dista...

Active, not recruiting
Onychomycosis
Drug: MOB015B
Drug: Vehicle (Placebo Comparator)

Trial sponsors

Takeda logo
Acrotech Biopharma logo
Bayer logo
D
M
N
Novo Nordisk logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems